The FDA accepted the drug Xolair earlier this month, making it the primary treatment accepted to scale back allergic reactions after unintended exposures.
MICHEL MARTIN, HOST:
A brand new research printed within the New England Journal of Medication reveals simply how efficient an outdated bronchial asthma drug could be in stopping allergic reactions in individuals with meals allergy symptoms. NPR’s Allison Aubrey stories the FDA accepted the drug earlier this month, making it the primary treatment accepted to scale back allergic reactions after unintended exposures.
ALLISON AUBREY, BYLINE: For plenty of households with meals allergy symptoms, there’s fixed fear. So when a possibility got here alongside to take part in a trial of a drug that might assist stop allergic reactions, Ann Marqueling and her husband, Kevin Wang, jumped on the probability. Their 5-year-old son is allergic to a number of meals, together with peanuts and eggs.
KEVIN WANG: More often than not, it is this fixed vigilance as a result of, , he will get a whiff of peanut butter, he can go into anaphylactic shock. So until you reside with it, you do not perceive how anxious you will get.
AUBREY: Each few weeks for about 4 months, they gave their son an injection. The drug being examined, referred to as Xolair, has been available on the market for years to deal with bronchial asthma and hives. Now researchers at Stanford had been evaluating how effectively it will probably stop reactions in individuals who’ve consumed small quantities of meals they’re allergic to. Ann Marqueling says their son appeared to enhance considerably.
ANN MARQUELING: That was reassuring for us, even simply to see him having the ability to tolerate greater than he had in the beginning.
AUBREY: Dr. Sharon Chinthrajah of Stanford College is the research’s senior creator. She discovered after 4 months on the drug, many of the contributors taking Xolair had been in a position to eat some peanut with out getting a severe allergic response.
SHARON CHINTHRAJAH: Two-thirds of these sufferers had been in a position to tolerate as much as 600 mg of peanut and as much as 1,000 mg of different meals, which is wonderful. Some sufferers had been even in a position to tolerate far more than that.
AUBREY: She says taking the drug does not imply that folks can now begin consuming the meals they’re allergic to. The hope for the long run is that there shall be methods to stop or reverse meals allergy symptoms. However for now, the thought is to present sufferers peace of thoughts in the event that they by chance eat a meals they’re allergic to.
CHINTHRAJAH: The concept is that this treatment will add a further layer of safety.
AUBREY: Dr. Alkis Togias is an immunologist on the Nationwide Institute of Allergy and Infectious Ailments. He explains individuals with meals allergy symptoms produce immunoglobulin E, referred to as IgE. It is a kind of antibody to meals they cannot tolerate. Xolair works by binding to the IgE and halting a response.
ALKIS TOGIAS: So Xolair takes away IgE, and there may be little or no IgE left to trigger an allergic response. And it’s a breakthrough as a result of it gives, for the primary time, an possibility for sufferers with a number of meals allergy symptoms.
AUBREY: Ann Marqueling and Kevin Wang say mother and father might really feel much less strain to always monitor all the pieces their baby is consuming.
MARQUELING: We really feel far more snug. You realize, we’re not going to feed him peanut butter sandwiches, however we really feel a lot snug saying, you’ll be able to go to Charlie’s occasion, and we do not have to ask beforehand, hey, Charlie, keep in mind, no nuts, no peanuts, no tree nuts, no eggs, blah, blah, blah.
AUBREY: They are saying they do not really feel they should helicopter his each transfer, which makes it simpler for everybody.
Allison Aubrey, NPR Information.
(SOUNDBITE OF SKYWAY MAN’S “DINNER WITH THE NEIGHBOR’S KIDS”)
Copyright © 2024 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional data.
NPR transcripts are created on a rush deadline by an NPR contractor. This textual content will not be in its closing type and could also be up to date or revised sooner or later. Accuracy and availability might range. The authoritative report of NPR’s programming is the audio report.
